ISRCTN96705420
Completed
未知
The CREAM Study:? ChildRen with Eczema, Antibiotic Management Study: a randomised controlled trial
Cardiff University (UK)0 sites510 target enrollmentJune 27, 2012
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Cardiff University (UK)
- Enrollment
- 510
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
2016 results in: http://www.ncbi.nlm.nih.gov/pubmed/26938214
Investigators
Eligibility Criteria
Inclusion Criteria
- •Children (aged 3 months to less than five years) with atopic eczema (as defined by UK working party criteria) who are presenting in primary care and their treating clinician suspects infected eczema because of at least one of the following:
- •The UK working party criteria state that in order to qualify as a case of atopic eczema with the UK diagnostic criteria, the child MUST have:
- •1\. An itch skin condition in the last 12 months
- •2\. And three or more of the following:
- •2\.1\. Onset below age 2 (Not used in children under 4 years old)
- •2\.2\.History of flexural involvement.
- •2\.3\. History of general dry skin atopic disease (In children aged under 4 years old, history of atopic disease in a first degree relative may be included)
- •2\.4\. Personal history of other atopic disease
- •3\. The eczema is failing to respond to standard treatment
- •4\. There is a flare in the severity or extent of the eczema
Exclusion Criteria
- •1\. Use of oral or topical antibiotics in the past week
- •2\. Use of potent (Betamethasone valerate 0\.1%, Betacap, Betesil, Bettamousse, Betnovate, Cutivate, Diprosone, Elocon, Hydrocortisone butyrate, Locoid, Locoid Crelo, Metosyn, Nerisone, Synalar, Aureocort, Betnovate\-C, Betnovate\-N, Fucibet, Lotriderm, Synalar C, Synalar N, Diprosalic) or very potent (Clarelux, Dermovate, Etrivex, Nerisone Forte, Dermovate\-NN) corticosteroids within the past week
- •3\. Immune suppression
- •4\. Features suggestive of eczema herpeticum (significant pain, punched out lesions)
- •5\. Severe infection (systemic upset, cellulitis) ) and/or suspected infection warrants immediate hospitalisation or urgent dermatology referral
- •6\. Severity of eczema
- •7\. Known renal and / or hepatic impairment
- •8\. Allergy to penicillin and erythromycin or allergy to penicillin and contraindication to erythromycin, such as current use of medication that is known to interact with erythromycin
- •9\. Allergy the fusidic acid
- •10\. Current use of any medication that is known to interact with fuscidic acid
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
The CREAM Study - Children with Eczema Antibiotic Management StudyEUCTR2011-003591-37-GBCardiff University113
Active, not recruiting
Not Applicable
A Pilot Study of Efficacy and Safety of SIM05 in Adults with Atopic EczemaAtopic EczemaNCT06230991Chinese University of Hong Kong30
Completed
Phase 4
Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic DermatitisAtopic DermatitisNCT00828412Promius Pharma, LLC100
Completed
Phase 2
The PEBBLES study: Prevention of Eczema By a Barrier Lipid Equilibrium StrategyeczemaSkin - Dermatological conditionsACTRN12613000472774Murdoch Childrens Research Institute80
Completed
Not Applicable
GB-EZ-SIM03 Probiotics Study for Childhood EczemaEczemaNCT05607511Chinese University of Hong Kong20